Anti-Human Thymic Stromal Lymphopoietin (TSLP) (Tezepelumab) (T-GRP)

Thymic stromal lymphopoietin (TSLP) is a pleiotropic, epithelium-derived cytokine that is characterized as a lymphocyte growth factor1. TSLP plays a key role in the inflammatory response of the lung, such as in asthma and COPD pathobiology. To function, TSLP engages a heteromeric complex of TSLP receptor chain and interleukin 7 receptor-α (IL-7Rα) to induce STAT5. TSLP can be expressed as either a long or short isoform. It is the long isoform that is specifically upregulated by inflammatory stimuli in human bronchial epithelial cells and macrophages. In contrast, the short isoform is constitutively expressed in bronchial and colonic epithelial cells, lung fibroblasts, macrophages, and keratinocytes. TSLP mediates airway structural cell and immune cell interactions 2 . TSLP activity is upstream of the asthma inflammatory cycle making it an effective target for treatment. MEDI9929 (Tezepelumab) is a fully human monoclonal antibody developed for the treatment of asthma, COPD, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and eosinophilic esophagitis2. Tezepelumab inhibits the action of TSLP by blocking interaction with its receptor TSLPR. Tezepelumab reduces T2 inflammatory biomarkers, including airway eosinophil counts, when administered in vivo3,4,5.